AXIM (AXIM Biotechnologies) Total Stockholders Equity: $-10.43 Mil (As of Jun. 2025)


What is AXIM Biotechnologies Total Stockholders Equity?

AXIM Biotechnologies AXIM -14.63% Total Stockholders Equity is $-10.43 Mil as of Jun. 2025.

AXIM Biotechnologies's Total Stockholders Equity for the quarter that ended in Jun. 2025 was $-10.43 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. AXIM Biotechnologies's Book Value per Share for the quarter that ended in Jun. 2025 was $-0.03. The ratio of a company's debt over equity can be used to measure how leveraged this company is. AXIM Biotechnologies's Debt-to-Equity for the quarter that ended in Jun. 2025 was -0.72.

AXIM Biotechnologies  (OTCPK:AXIM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

AXIM Biotechnologies's Book Value per Share for the quarter that ended in Jun. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-10.426-0)/332.957
=-0.03

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

AXIM Biotechnologies's Debt-to-Equity for the quarter that ended in Jun. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.102 + 7.444) / -10.426
=-0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Total Stockholders Equity Related Terms

AXIM Biotechnologies Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Total Stockholders Equity Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.57 -2.34 -4.83 -7.66 -10.42

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.45 -9.54 -10.42 -10.64 -10.43
What does a Total Stockholders Equity of $-10.43 Mil mean?
AXIM Biotechnologies (AXIM) has a Total Stockholders Equity of $-10.43 Mil as of Jun. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for AXIM Biotechnologies and its competitors.
Is AXIM Biotechnologies' Total Stockholders Equity too high?
AXIM Biotechnologies' current Total Stockholders Equity is $-10.43 Mil.
How does AXIM Biotechnologies' Total Stockholders Equity compare to ZVSA and HEPA?
AXIM Biotechnologies' Total Stockholders Equity of $-10.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for AXIM Biotechnologies and its competitors. AXIM Biotechnologies's current Total Stockholders Equity is $-10.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Total Stockholders Equity of $-10.43 Mil. The current Total Stockholders Equity is $-10.43 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Total Stockholders Equity is $-10.43 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.